HilleVax (NASDAQ:HLVX) stock is falling hard on Monday following the release of topline data from its Phase 2b clinical trial of HIL-214 in infants.
This clinical trial studied the efficacy, safety and immunogenicity of HIL-214 as a norovirus vaccine for infants. Unfortunately for HLVX investors, the study only showed an efficacy of 5% for the vaccine.
To go along with this, HilleVax said that it saw no benefits from the secondary endpoints of its clinical trial. HilleVax will stop the development of HIL-214 as an infant vaccine but is considering further testing as an adult vaccine.
HilleVax CEO Rob Hershberg said the following about the news:
“We are disappointed that the NEST-IN1 study did not meet its primary efficacy endpoint […] While HIL-214 previously showed clinical benefit in adults, NEST-IN1 was the first efficacy study conducted in infants for a norovirus vaccine candidate. We believe the efficacy in the infant setting may have been impacted by the appearance of multiple emerging GII.4 strains in this trial.”
How This Affects HLVX Stock
Shares of HLVX stock are taking a beating alongside heavy trading today. This has more than 17 million shares traded as investors offload the stock on the failed clinical trial news. To put that number in perspective, the company’s daily average trading volume is about 200,000 shares.
HLVX stock is down 87.3% as of Monday afternoon.
Investors will want to stick around for more of the most recent stock market news today!
We have all of the hottest stock market happenings worth reading about on Monday. That includes all of the latest details on Virpax Pharmaceuticals (NASDAQ:VRPX), Rivian (NASDAQ:RIVN) and Microsoft (NASDAQ:MSFT) shares today. You can catch up on all of these matters by checking out the links below!
More Monday Stock Market News
- Why Is Virpax Pharmaceuticals (VRPX) Stock Up 97% Today?
- RIVN Stock Alert: Rivian Chief Accounting Officer Jeffrey Baker Resigns
- Microsoft Layoffs 2024: What to Know as MSFT Enacts More Job Cuts
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
